Friday, July 10, 2026
🇺🇸 FDA

pharma · Relapsed or Refractory Multiple Myeloma (RRMM) · Relapsed and/or Refractory Multiple Myeloma

Celgene

Celgene Europe Limited

Celgene trial registry — 45 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Summit, USA HQ
2,104 Employees
EMA registrant Type
Company details
Status
Public
HQ
Summit, USA
Employees
2,104
Programs
45
Drugs
91
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

Celgene clinical trials

Registry index of 45 ClinicalTrials.gov studies linked to Celgene programs — each row shows trial ID, program name, phase, status, and indication.

Celgene trial registry — 45 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Celgene.

  1. CA1190002 — Phase 1

    Clinical update

  2. RPC01-3203 — Phase 3

    Clinical update

  3. IM047-023 — Phase 3

    Clinical update

  4. FEDR-MF-002 — Phase 3

    Clinical update

  5. CC-92480-MM-001 — Phase 2

    Clinical update

  6. CC-90011-SCLC-001 — Phase 1

    Clinical update

  7. CC-90010-ST-001 — Phase 1

    Clinical update

  8. CC-90010-GBM-002 — Phase 1

    Clinical update

Trial registry

45 studies
  5. 2023-505183-10-00

    idecabtagene vicleucel

    Phase 2 active small_molecule

    Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)

    CTIS ↗
  17. 2023-509848-10-00

    BB2121-MM-003

    Phase 3 active small_molecule

    Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.

    CTIS ↗
  19. 2023-509969-20-00

    CC-90010-ST-001

    Phase 1 active other

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    CTIS ↗
  33. 2024-515690-10-00

    CC-99282-NHL-001

    Phase 2 active small_molecule

    Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.